A new digital health intervention, developed over a decade of research, uses a gamified app to help reduce depressive symptoms by disrupting ruminative thought patterns.
Pursuant to the terms of licensing agreement, MycoMedica will seek to develop EB-002, formerly EB-373, a synthetic prodrug of the active metabolite psilocin, in treatment of neuropsychiatric disorders ...